Enveloped viruses obtain their envelopes during the process of budding from infected cells. During this process, however, these viruses acquire parts of the host cell membranes and host cell-derived proteins as integral parts of their mature envelopes. These host-derived components of viral envelopes may subsequently exhibit various effects on the life cycle of the virus; virus cell interactions, especially host response to virus-incorporated self-proteins; and the pathogenesis of the disease induced by these viruses. Although it was known for some time that various viruses incorporate host cell-derived proteins, the issue of the role of these proteins has received increased attention, specifically in connection with human immunodeficiency virus (HIV) infection and development of acquired immunodeficiency syndrome (AIDS) in humans. The aim of this review is to summarize our current knowledge of the analysis and role of host-derived proteins associated with enveloped viruses, with emphasis on the potential role of these proteins in the pathogenesis of AIDS. Clearly, differences in the clinical outcome of those nonhuman primates infected with simian immunodeficiency virus (SIV) that are disease resistant compared with SIV-infected species that are disease susceptible provide a unique opportunity to determine whether differences in the incorporation of distinct sets of host proteins play a role with distinct clinical outcomes.
KimFJ, BattiniJL, ManelN, SitbonM.Emergence of vertebrate retroviruses and envelope capture. Virology318: 183–191, 2004.
2.
BriggsJA, WilkT, FullerSD. Do lipid rafts mediate virus assembly and pseudotyping?J Gen Virol84: 757–768, 2003.
3.
LetvinNL, KingNW. Immunologic and pathologic manifestations of the infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Acquir Immune Defic Syndr3: 1023–1040, 1990.
4.
KestlerH, KodamaT, RinglerD, MarthasM, PedersenN, LacknerA, RegierD, SehgalP, DanielM, KingN, DesrosiersR.Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science248: 1109–1112, 1990.
5.
NayakDP, HuiEK. The role of lipid microdomains in virus biology. Subcell Biochem37: 443–491, 2004.
MoritaE, SundquistWI. Retrovirus budding. Annu Rev Cell Dev Biol20: 395–425, 2004.
12.
EdidinM.The state of lipid rafts: from model membranes to cells. Annu Rev Biophys Biomol Struct32: 257–283, 2003.
13.
HorejsiV.The roles of membrane microdomains (rafts) in T cell activation. Immunol Rev191: 148–164, 2003.
14.
LescarJ, RousselA, WienMW, NavazaJ, FullerSD, WenglerG, ReyFA. The fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell105: 137–148, 2001.
15.
BhattacharyaJ, PetersPJ, ClaphamPR. Human immunodeficiency virus type 1 envelope glycoproteins that lack cytoplasmic domain cysteines: impact on association with membrane lipid rafts and incorporation onto budding virus particles. J Virol78: 5500–5506, 2004.
16.
Pelchen-MatthewsA, KramerB, MarshM.Infectious HIV-1 assembles in late endosomes in primary macrophages. J Cell Biol162: 443–455, 2003.
17.
HolmK, WeclewiczK, HewsonR, SuomalainenM.Human immunodeficiency virus type 1 assembly and lipid rafts: Pr55gag associates with membrane domains that are largely resistant to Brij98 but sensitive to Triton X-100. J Virol77: 4805–4817, 2003.
18.
RoussoI, MixonMB, ChenBK, KimPS. Palmitoylation of the HIV-1 envelope glycoprotein is critical for viral infectivity. Proc Nad Acad Sci U S A97: 13523–13525, 2000.
19.
NguyenDH, HildrethJE. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol74: 3264–3272, 2000.
20.
GrahamDR, ChertovaE, HilbumJM, ArthurLO, HildrethJE. Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with β-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts. J Virol77: 8237–8248, 2003.
21.
BeausejourY, TremblayMJ. Envelope glycoproteins are not required for insertion of host ICAM-1 into human immunodeficiency virus type 1 and ICAM-1-bearing viruses are still infectious despite a suboptimal level of trimeric envelope proteins. Virology324: 165–172, 2004.
PicklWF, Pimentel-MuinosFX, SeedB.Lipid rafts and pseudotyping. J Virol75: 7175–7183, 2001.
24.
TremblayMJ, FortinJF, CantinR.The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today19: 346–351, 1998.
25.
OrentasRJ, HildrethJE. Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV. AIDS Res Hum Retroviruses9: 1157–1165, 1993.
26.
EsserMT, GrahamDR, CorenLV, TrubeyCM, BessJWJr.Differential incorporation of CD45, CD80 (B7–1), CD86 (B7–2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation. J Virol75: 6173–6182, 2001.
27.
AloiaRC, TianH, JensenFC. Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc Natl Acad Sci U S A90: 5181–5185, 1993.
28.
AloiaRC, JensenFC, CurtainCC, MobleyPW, GordonLM. Lipid composition and fluidity of the human immunodeficiency virus. Proc Natl Acad Sci U S A85: 900–904, 1988.
29.
LiaoZ, GrahamDR, HildrethJE. Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells. AIDS Res Hum Retroviruses19: 675–687, 2003.
30.
LawnSD, RobertsBD, GriffinGE, FolksTM, ButeraST. Cellular compartments of human immunodeficiency virus type 1 replication in vivo: determination by presence of virion-associated host proteins and impact of opportunistic infection. J Virol74: 139–145, 2000.
31.
NguyenDG, BoothA, GouldSJ, HildrethJE. Evidence that HIV budding in primary macrophages occurs through the exosome release pathway. J Biol Chem278: 52347–52354, 2003.
32.
RaposoG, MooreM, InnesD, LeijendekkerR, Leigh-BrownA, BenarochP, GeuzeH.Human macrophages accumulate HIV-1 particles in MHC II compartments. Traffic3: 718–729, 2002.
33.
RabesandratanaH, ToutantJP, ReggioH, VidalM.Decay-accelerating factor (CD55) and membrane inhibitor of reactive lysis (CD59) are released within exosomes during in vitro maturation of reticulocytes. Blood91: 2573–2580, 1998.
34.
HeijnenHF, SchielAE, FijnheerR, GeuzeHJ, SixmaJJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and α-granules. Blood94: 3791–3799, 1999.
35.
WhitesideTL. Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system?Br J Cancer92: 209–211, 2005.
36.
TaylorDD, Gercel-TaylorC.Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer92: 305–311, 2005.
37.
SkokosD, Le PanseS, VillaI, RousselleJC, PeronetR, DavidB, NamaneA, MecheriS.Mast cell-dependent B and T lymphocyte activation is mediated by the secretion of immunologically active exosomes. J Immunol166: 868–876, 2001.
38.
BlanchardN, LankarD, FaureF, RegnaultA, DumontC, RaposoG, HivrozC.TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J Immunol168: 3235–3241, 2002.
39.
ArnoldPY, MannieMD. Vesicles bearing MHC class II molecules mediate transfer of antigen from antigen-presenting cells to CD4+ T cells. Eur J Immunol29: 1363–1373, 1999.
40.
PatelDM, ArnoldPY, WhiteGA, NardellaJP, MannieMD. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition. J Immunol163: 5201–5210, 1999.
DenzerK, KleijmeerMJ, HeijnenHF, StoorvogelW, GeuzeHJ. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 113 Pt19: 3365–3374, 2000.
44.
StoorvogelW, KleijmeerMJ, GeuzeHJ, RaposoG.The biogenesis and functions of exosomes. Traffic3: 321–330, 2002.
45.
GluschankofP, MondorI, GelderblomHR, SattentauQJ. Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations. Virology230: 125–133, 1997.
46.
BessJWJr.Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology230: 134–144, 1997.
47.
GouldSJ, BoothAM, HildrethJE. The Trojan exosome hypothesis. Proc Natl Acad Sci U S A100: 10592–10597, 2003.
48.
SheppardHW, AscherMS. The relationship between AIDS and immunologic tolerance. J Acquir Immune Defic Syndr5: 143–147, 1992.
49.
SheppardHW, AscherMS. The natural history and pathogenesis of HIV infection. Annu Rev Microbiol46: 533–564, 1992.
50.
FultzPN, McClureHM, AndersonDC, SwensonRB, AnandR, SrinivasanA.Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys). Proc Natl Acad Sci U S A83: 5286–5290, 1986.
51.
BostikP, DoddGL, AnsariAA. CD4+ T cell signaling in the natural SIV host—implications for disease pathogenesis. Front Biosci8:s904–s912, 2003.
52.
AnsariAA, OnlamoonN, BostikP, MayneAE, GarganoL, PattanapanyasatK.Lessons learnt from studies of the immune characterization of naturally SIV infected sooty mangabeys. Front Biosci8:s1030–s1050, 2003.
53.
Rey-CuilleMA, BerthierJL, Bomsel-DemontoyMC, ChaducY, MontagnierL, HovanessianAG, ChakrabartiLA. Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. J Virol72: 3872–3886, 1998.
54.
LetvinNL, EatonKA, AldrichWR, SehgalPK, BlakeBJ, SchlossmanSF, KingNW, HuntRD. Acquired immunodeficiency syndrome in a colony of macaque monkeys. Proc Natl Acad Sci U S A80: 2718–2722, 1983.
55.
BechtelJT, WinantRC, GanemD.Host and viral proteins in the virion of Kaposi's sarcoma-associated herpesvirus. J Virol79: 4952–4964, 2005.
56.
OttDE. Potential roles of cellular proteins in HIV-1. Rev Med Virol12: 359–374, 2002.
57.
OttDE. Cellular proteins in HIV virions. Rev Med Virol7: 167–180, 1997.
58.
LenschowDJ, WalunasTL, BluestoneJA. CD28/B7 system of T cell costimulation. Annu Rev Immunol14: 233–258, 1996.
59.
MedemaJP, BorstJ.T cell signaling: a decision of life and death. Hum Immunol60: 403–411, 1999.
60.
FrauwirthKA, AlegreML, ThompsonCB. Induction of T cell anergy in the absence of CTLA-4/B7 interaction. J Immunol164: 2987–2993, 2000.
61.
NoelPJ, BoiseLH, GreenJM, ThompsonCB. CD28 costimulation prevents cell death during primary T cell activation. J Immunol157: 636–642, 1996.
62.
MartinG, TremblayMJ. HLA-DR, ICAM-1, CD40, CD40L, and CD86 are incorporated to a similar degree into clinical human immunodeficiency virus type 1 variants expanded in natural reservoirs such as peripheral blood mononuclear cells and human lymphoid tissue cultured ex vivo. Clin Immunol111:275–285, 2004.
63.
GiguereJF, BounouS, PaquetteJS, MadrenasJ, TremblayMJ. Insertion of host-derived costimulatory molecules CD80 (B7.1) and CD86 (B7.2) into human immunodeficiency virus type 1 affects the virus life cycle. J Virol78: 6222–6232, 2004.
64.
GiguereJF, PaquetteJS, BounouS, CantinR, TremblayMJ. New insights into the functionality of a virion-anchored host cell membrane protein: CD28 versus HIV type 1. J Immunol169: 2762–2771, 2002.
65.
ScholsD, PauwelsR, DesmyterJ, De ClercqE.Presence of class II histocompatibility DR proteins on the envelope of human immunodeficiency virus demonstrated by FACS analysis. Virology189: 374–376, 1992.
66.
SaarloosMN, SullivanBL, CzerniewskiMA, ParameswarKD, SpearGT. Detection of HLA-DR associated with monocytotropic, primary, and plasma isolates of human immunodeficiency virus type 1. J Virol71: 1640–1643, 1997.
67.
HendersonLE, SowderR, CopelandTD, OroszlanS, ArthurLO, RobeyWG, FischingerPJ. Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III. J Virol61: 629–632, 1987.
68.
CantinR, FortinJF, LamontagneG, TremblayM.The acquisition of host-derived major histocompatibility complex class II glycoproteins by human immunodeficiency virus type 1 accelerates the process of virus entry and infection in human T-lymphoid cells. Blood90: 1091–1100, 1997.
69.
CantinR, FortinJF, LamontagneG, TremblayM.The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity. J Virol71: 1922–1930, 1997.
70.
ArthurLO, BessJWJr.Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science258: 1935–1938, 1992.
71.
BounouS, DumaisN, TremblayMJ. Attachment of human immunodeficiency virus-1 (HIV-1) particles bearing host-encoded B7–2 proteins leads to nuclear factor-κB- and nuclear factor of activated T cells-dependent activation of HIV-1 long terminal repeat transcription. J Biol Chem276: 6359–6369, 2001.
72.
RoyJ, MartinG, GiguereJF, BelangerD, PetrinM, TremblayMJ. HIV type 1 can act as an APC upon acquisition from the host cell of peptide-loaded HLA-DR and CD86 molecules. J Immunol174: 4779–4788, 2005.
73.
RossioJL, BessJJr.HLA class II on HIV particles is functional in superantigen presentation to human T cells: implications for HIV pathogenesis. AIDS Res Hum Retroviruses11: 1433–1439, 1995.
HoxieJA, FitzharrisTP, YoungbarPR, MatthewsDM, RackowskiJL, RadkaSF. Nonrandom association of cellular antigens with HTLV-III virions. Hum Immunol18: 39–52, 1987.
77.
BenkiraneM, Blanc-ZouaouiD, HirnM, DevauxC.Involvement of human leukocyte antigen class I molecules in human immunodeficiency virus infection of CD4-positive cells. J Virol68: 6332–6339, 1994.
78.
CastellinoF, ZhongG, GermainRN. Antigen presentation by MHC class II molecules: invariant chain function, protein trafficking, and the molecular basis of diverse determinant capture. Hum Immunol54: 159–169, 1997.
79.
HollingTM, SchootenE, van Den ElsenPJ. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Hum Immunol65: 282–290, 2004.
80.
Al-DaccakR, MooneyN, CharronD.MHC class II signaling in antigen-presenting cells. Curr Opin Immunol16: 108–113, 2004.
81.
CantinR, FortinJF, TremblayM.The amount of host HLA-DR proteins acquired by HIV-1 is virus strain- and cell type-specific. Virology218: 372–381, 1996.
82.
DoyleC, StromingerJL. Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature330: 256–259, 1987.
83.
DalgleishAG, BeverleyPC, ClaphamPR, CrawfordDH, GreavesMF, WeissRA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature312: 763–767, 1984.
84.
KlatzmannD, ChampagneE, ChamaretS, GruestJ, GuetardD, HercendT, GluckmanJC, MontagnierL.T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature312: 767–768, 1984.
85.
KlatzmannD, Barre-SinoussiF, NugeyreMT, DanquetC, VilmerE, GriscelliC, Brun-VeziretF, RouziouxC, GluckmanJC, ChermannJC, MontagnierL.Selective tropism of Iymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science225: 59–63, 1984.
86.
McDougalJS, MaddonPJ, DalgleishAG, ClaphamPR, LiftmanDR, GodfreyM, MaddonDE, ChessL, WeissRA, AxelR.The T4 glycoprotein is a cell-surface receptor for the AIDS virus. Cold Spring Harb Symp Quant Biol51(Pt 2):703–711, 1986.
87.
KampW, BreijEC, NottetHS, BerkMB. Interactions between major histocompatibility complex class II surface expression and HIV: implications for pathogenesis. Eur J Clin Invest31: 984–991, 2001.
88.
GuoMM, HildrethJE. HIV acquires functional adhesion receptors from host cells. AIDS Res Hum Retroviruses11: 1007–1013, 1995.
89.
BounouS, LeclercJE, TremblayMJ. Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4+-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J Virol76: 1004–1014, 2002.
90.
BastianiL, LaalS, KimM, Zolla-PaznerS.Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J Virol71: 3444–3450, 1997.
91.
GomezMB, HildrethJE. Antibody to adhesion molecule LFA-1 enhances plasma neutralization of human immunodeficiency virus type 1. J Virol69: 4628–4632, 1995.
92.
MarlinSD, SpringerTA. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell51: 813–819, 1987.
93.
DustinML, SpringerTA. Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Annu Rev Immunol9: 27–66, 1991.
94.
PaquetteJS, FortinJF, BlanchardL, TremblayMJ. Level of ICAM-1 surface expression on virus producer cells influences both the amount of virion-bound host ICAM-1 and human immunodeficiency virus type 1 infectivity. J Virol72: 9329–9336, 1998.
95.
HioeCE, ChienPCJr.LFA-1 expression on target cells promotes human immunodeficiency virus type 1 infection and transmission. J Virol75: 1077–1082, 2001.
96.
FortinJF, CantinR, LamontagneG, TremblayM.Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol71: 3588–3596, 1997.
97.
FortinJF, CantinR, TremblayMJ. T cells expressing activated LFA-1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM-1. J Virol72: 2105–2112, 1998.
98.
GiguereJF, TremblayMJ. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol78: 12062–12065, 2004.
99.
GasqueP.Complement: a unique innate immune sensor for danger signals. Mol Immunol41: 1089–1098, 2004.
100.
SaifuddinM, HedayatiT, AtkinsonJP, HolguinMH, ParkerCJ, SpearGT. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol78(Pt 8):1907–1911, 1997.
101.
SaifuddinM, ParkerCJ, PeeplesME, GornyMK, Zolla-PaznerS, GhassemiM, RooneyIA, AtkinsonJP, SpearGT. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med182: 501–509, 1995.
102.
SaifuddinM, GhassemiM, PatkiC, ParkerCJ, SpearGT. Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis. AIDS Res Hum Retroviruses10: 829–837, 1994.
103.
MarschangP, SodroskiJ, WurznerR, DierichMP. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol25: 285–290, 1995.
104.
SpearGT, LurainNS, ParkerCJ, GhassemiM, PayneGH, SaifuddinM.Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol155: 4376–4381, 1995.
105.
VanderplasschenA, MathewE, HollinsheadM, SimRB, SmithGL. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci U S A95: 7544–7549, 1998.
106.
KraussO, HollinsheadR, HollinsheadM, SmithGL. An investigation of incorporation of cellular antigens into vaccinia virus particles. J Gen Virol83: 2347–2359, 2002.
107.
SullivanBL, KnopoffEJ, SaifuddinM, TakefmanDM, SaarloosMN, ShaBE, SpearGT. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. J Immunol157: 1791–1798, 1996.
108.
BounouS, GiguereJF, CantinR, GilbertC, ImbeaultM, MartinG, TremblayMJ. The-importance of virus-associated host ICAM-1 in human immunodeficiency virus type 1 dissemination depends on the cellular context. FASEB J18: 1294–1296, 2004.
109.
EsserMT, BessJWJr.Partial activation and induction of apoptosis in CD4+ and CD8+ T lymphocytes by conformationally authentic noninfectious human immunodeficiency virus type 1. J Virol75: 1152–1164, 2001.
110.
LawnSD, ButeraST. Incorporation of HLA-DR into the envelope of human immunodeficiency virus type 1 in vivo: correlation with stage of disease and presence of opportunistic infection. J Virol74: 10256–10259, 2000.
111.
FrankI, KacaniL, StoiberH, StosselH, SpruthM, SteindlF, RomaniN, DienenMP. Human immunodeficiency virus type 1 derived from cocultures of immature dendritic cells with autologous T cells carries T-cell-specific molecules on its surface and is highly infectious. J Virol73: 3449–3454, 1999.
112.
CheliusD, HuhmerAF, ShiehCH, LehmbergE, TrainaJA, SlatteryTK, PungorEJr.Analysis of the adenovirus type 5 proteome by liquid chromatography and tandem mass spectrometry methods. J Proteome Res1: 501–513, 2002.
113.
JohannsenE, LuftigM, ChaseMR, WeickselS, Cahir-McFarlandE, IllanesD, SarracinoD, KieffE.Proteins of purified Epstein-Barr virus. Proc Natl Acad Sci U S A101: 16286–16291, 2004.
114.
KattenhornLM, MillsR, WagnerM, LomsadzeA, MakeevV, BorodovskyM, PloeghHL, KesslerBM. Identification of proteins associated with murine cytomegalovirus virions. J Virol78: 11187–11197, 2004.
115.
VarnumSM, StreblowDN, MonroeME, SmithP, AuberryKJ, Pasa-TolicL, WangD, CampDGII, RodlandK, WileyS, BrittW, ShenkT, SmithRD, NelsonJA. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol78: 10960–10966, 2004.
